Vaccine represents one of the most attractive and fast growing sectors, with
players' revenue exceeding their expectations. The global vaccine market is
primarily divided into adult and pediatric segments, further classified into
several other sub-segments. Both the adult and pediatric vaccine sectors have
sustained the growth momentum and industry participants have been devising
strategies to enlarge their presence in these segments.
According to our new research report, " Global Vaccine Market Forecast to
2013" , the global vaccine market is likely to reach an amount worth to US$
27.6 Billion by the end of 2011, on the back of key factors, such as high
growth in emerging markets, technological advancements, strong support from
government, and other active associations like WHO and GAVI and increased
investment in research activities. With the successful launch of new vaccines
in the coming years for key indications, the market for vaccines may further
exhibit good performance and it is estimated that the market will reach to the
mark of US$ 33 Billion by 2013.
Our analysis of the global vaccine market illustrates that a large number of
players are spending huge amount on the aspect of research and development.
This is mainly due to the fact that the successful launch of very first
vaccine products for any virus may significantly impact the market share.
Currently, the companies are actively participating in the trials of vaccines
for cancer, malaria, tuberculosis, HIV/AIDS, among others.
The report " Global Vaccine Market Forecast to 2013" , provides an in-depth
analysis of the global vaccine market by focusing on key countries of the
world. It investigates the current market trends and analyzes their impact on
the overall market performance in a broad way. Moreover, the report identifies
all the necessary factors and aspects related to market and represent current
industry status with future forecast on vaccine types and countries for
2010-2013. In addition, the description of key players and their recent
activities have been provided to showcase an effective and balanced outlook of
the global vaccine market.
Table of Contents
Table of Contents
1. Analyst View
2. Research Methodology
3. Market Overview
4. Key Market Drivers
4.1 Improved Routine Immunization
4.2 Emerging Markets
4.3 Technological Developments
4.4 Investment in Vaccine Research
5. Emerging Trends
5.1 DNA Vaccines: Gaining Popularity
5.2 M&As in Vaccine Market
5.3 Vaccine Delivery Advancements
6. Pediatric Vaccines
6.1 Pneumococcal
6.2 Polio
6.3 Varicella
6.4 Meningococcal
6.5 Rotavirus
6.6 DTP
6.7 Measles, Mumps & Rubella (MMR)
6.8 Tuberculosis
7. Adult/Travel & Therapeutic Vaccines
7.1 Hepatitis B
7.2 Malaria
7.3 Yellow Fever
7.4 Rabies
7.5 Japanese Encephalitis
7.6 Typhoid
7.7 West Nile
7.8 HIV
7.9 Cancer
7.10 Influenza
8. Key Geographical Markets
8.1 US
8.1.1 Market Overview
8.1.2 Key Players
8.1.3 Product Portfolio
8.2 Europe
8.2.1 Market Overview
8.2.2 Key Players
8.2.3 Product Portfolio
8.3 China
8.3.1 Market Overview
8.3.2 Key Players
8.3.3 Product Portfolio
8.4 India
8.4.1 Market Overview
8.4.2 Key Players
8.4.3 Product Portfolio
8.5 Japan
8.5.1 Market Overview
8.5.2 Key Players
8.5.3 Product Portfolio
8.6 Brazil
8.6.1 Market Overview
8.6.2 Key Players
8.6.3 Product Portfolio
9. Restraints in Vaccine Industry
9.1 High R&D Cost
9.2 Lack of Infrastructure for Trials and Manufacturing
9.3 Vaccine Supply
9.4 Ineffective Distribution
10. Competitive Landscape
10.1 Sanofi-Aventis
10.2 Novartis
10.3 GSK
10.4 Pfizer
10.5 Merck & Co.
List of Figures:
Figure 3-1: Global - Vaccine Market (Billion US$), 2010-2013
Figure 4-1: Global - Vaccine R&D Investment by Region (%), 2010
Figure 5-1: Global - Key M&As in Vaccine Market (2005-2010)
Figure 6-1: Global - Causes of Deaths in Children (<5 Years) among
Low-income Countries (%), 2011
Figure 6-2: Global - Pneumococcal Vaccine Market (Billion US$), 2010-2013
Figure 6-3: Global - Number of Polio Incidences (2007-2010)
Figure 6-4: Global - Polio Vaccine Market (Billion US$), 2010-2013
Figure 6-5: Global - Varicella Vaccine Market (Billion US$), 2010-2013
Figure 6-6: Global - Meningococcal Vaccine Market (Million US$), 2010-2013
Figure 6-7: Global - Rotavirus Vaccine Market (Million US$), 2010-2013
Figure 6-8: Global - Rotavirus Vaccine Market by Region (%), 2010
Figure 6-9: Global - Number of Diphtheria Incidences by Region (2009 &
2010)
Figure 6-10: Global - Number of Ntetanus Incidences by Region (2009 & 2010)
Figure 6-11: Global - Number of Ttetanus Incidences by Region (2009 & 2010)
Figure 6-12: Global - Number of Pertussis Incidences by Region (2009 &
2010)
Figure 6-13: Global - Number of Measles Incidences by Region (2009 & 2010)
Figure 6-14: Global - Number of Mumps Incidences by Region ('000), 2009 &
2010
Figure 6-15: Global - Number of Rubella Incidences by Region (2009 & 2010)
Figure 6-16: Global - Number of Tuberculosis Incidences by Region (2008 &
2009)
Figure 7-1: Global - Hepatitis B Surface Antigen Prevalence (%)
Figure 7-2: Global - Hepatitis B Vaccine Market (Billion US$), 2010-2013
Figure 7-3: Global - Malaria Vaccines under Pipeline
Table 8-4: Japan - Sales of Top Domestic Vaccine Manufacturers (Million
JPY)
Table 9-1: Health Statistics in Developed and Developing Countries (%)
Table 10-1: Sanofi Aventis - Strengths and Weaknesses
Table 10-2: Novartis - Strengths and Weaknesses
Table 10-3: GSK - Strengths and Weaknesses
Table 10-4: Pfizer - Strengths and Weaknesses
Global Vaccine Market Forecast to 2013 published by RNCOS E-Services Pvt. Ltd. in November 11, 2011. This report consists of 140 Pages and the price starts from US $ 1500.
The contents of this page may be different from the latest version. Please contact us for details.
